EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

Gary S Sachs, Paul P Yeung, Ludmyla Rekeda, Arifulla Khan, Julie L Adams, Maurizio Fava

American Journal of Psychiatry · 01.03.2023 · 180 (3) · 241-251

DOI: 10.1176/appi.ajp.20220504 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Psychiatry, erschienen am 01.03.2023. Verfasst von Gary S Sachs und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Harvard Medical School, and Massachusetts General Hospital, Boston (Sachs, Fava); Signant Health, Blue Bell, Penn. (Sachs);…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The purpose of this study was to investigate the efficacy of cariprazine, a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist, as adjunctive therapy for patients with major depressive disorder and nonresponse to at least one antidepressant monotherapy. METHODS: In this double-blind placebo-controlled study, adults with major depressive disorder and inadequate response to antidepressants alone were randomized in a 1:1:1 ratio to placebo, cariprazine at 1.5 mg/day, or cariprazine at 3.0 mg/day. The primary outcome was change from baseline to week 6 in total score on the Montgomery-Åsberg Depression Rating Scale (MADRS). Least-squares mean differences were estimated in the modified intent-to-treat (mITT) population using a mixed-effects model for repeated measures with adjustment for multiple comparisons. RESULTS: The mITT population comprised 751 patients (placebo: N=249; cariprazine 1.5 mg/day: N=250; cariprazine 3.0 mg/day: N=252). At week 6, the mean reduction from baseline in MADRS total score was significantly greater with cariprazine 1.5 mg/day than with placebo (-14.1 vs. -11.5) but not with cariprazine 3.0 mg/day (-13.1). Significant differences between the cariprazine 1.5 mg/day and placebo groups were also observed at weeks 2 and 4. Meeting the MADRS response criteria was significantly more likely among patients receiving cariprazine 1.5 mg/day than placebo (44.0% vs. 34.9%); remission rates were not significantly different among groups. Common treatment-emergent adverse events (≥5% in either cariprazine group and twice the placebo rate) were akathisia and nausea. CONCLUSIONS: Adjunctive cariprazine at 1.5 mg/day demonstrated efficacy in reducing depressive symptoms in adults with major depressive disorder and inadequate response to antidepressants alone. Cariprazine was generally well tolerated, with a safety profile that was consistent with previous findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderAntipsychotic AgentsAdultHumansTreatment OutcomeAntidepressive AgentsDouble-Blind MethodPiperazines

Stichwörter der Autor:innen

Adjunctive treatmentcariprazineclinical drug studiesmajor depressive disorderrandomized controlled trial

Substanzen

Antipsychotic AgentsAntidepressive AgentscariprazinePiperazines

Autor:innen und Institutionen

  • Department of Psychiatry, Harvard Medical School, and Massachusetts General Hospital, Boston (Sachs, Fava); Signant Health, Blue Bell, Penn. (Sachs); AbbVie, Madison, N.J. (Yeung, Rekeda, Adams); Northwest Clinical Rese…

Zitieren

APA

Sachs, G. S., Yeung, P. P., Rekeda, L., Khan, A., Adams, J. L., & Fava, M. (2023). Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. American Journal of Psychiatry, 180(3), 241-251. https://doi.org/10.1176/appi.ajp.20220504

Vancouver

Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. American Journal of Psychiatry. 2023;180(3):241-251. doi:10.1176/appi.ajp.20220504

BibTeX
@article{Sachs2023,
  author = {Sachs, Gary S and Yeung, Paul P and Rekeda, Ludmyla and Khan, Arifulla and Adams, Julie L and Fava, Maurizio},
  title = {Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study},
  journal = {American Journal of Psychiatry},
  year = {2023},
  volume = {180},
  number = {3},
  pages = {241--251},
  doi = {10.1176/appi.ajp.20220504}
}
Kostenlos starten →